IRIS PubliCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.846
EU - Europa 1.566
AS - Asia 362
AF - Africa 115
SA - Sud America 19
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.823
SE - Svezia 466
IT - Italia 374
IE - Irlanda 312
DE - Germania 166
CN - Cina 125
CI - Costa d'Avorio 113
IN - India 58
SG - Singapore 50
GB - Regno Unito 40
FR - Francia 38
HK - Hong Kong 36
FI - Finlandia 30
RU - Federazione Russa 27
JP - Giappone 19
NL - Olanda 18
CA - Canada 17
ES - Italia 15
CZ - Repubblica Ceca 14
AU - Australia 11
TR - Turchia 11
TH - Thailandia 10
IR - Iran 9
UA - Ucraina 9
CH - Svizzera 8
RO - Romania 8
BR - Brasile 7
BE - Belgio 6
GR - Grecia 6
IQ - Iraq 6
KR - Corea 6
HU - Ungheria 5
ID - Indonesia 5
PE - Perù 5
SA - Arabia Saudita 5
HR - Croazia 4
IL - Israele 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CO - Colombia 3
MY - Malesia 3
PL - Polonia 3
TW - Taiwan 3
AT - Austria 2
BG - Bulgaria 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EU - Europa 2
ME - Montenegro 2
MX - Messico 2
NO - Norvegia 2
PK - Pakistan 2
RS - Serbia 2
SI - Slovenia 2
VN - Vietnam 2
AR - Argentina 1
BD - Bangladesh 1
EE - Estonia 1
JO - Giordania 1
KZ - Kazakistan 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
SC - Seychelles 1
Totale 3.922
Salva come PNG Salva come JPEG
Città #
Chandler 425
Ashburn 421
Dublin 308
Abidjan 113
Bremen 113
New York 102
Milan 101
Princeton 99
Beijing 77
Boston 74
Rome 60
Wilmington 39
Hong Kong 34
Washington 31
San Mateo 30
Pune 28
Chicago 26
Helsinki 24
Frankfurt am Main 17
Paris 17
Seattle 16
Hangzhou 14
London 14
Redwood City 14
Dearborn 13
Amsterdam 11
Brno 11
Singapore 11
Fairfield 10
Los Angeles 9
Boydton 8
Busto Arsizio 8
Chiang Mai 8
Norwalk 8
Cattolica 7
Houston 7
Montreal 7
Nanjing 7
Ōtsu 7
Brussels 6
Edinburgh 6
Lappeenranta 6
Redmond 6
Woodbridge 6
Andover 5
Atlanta 5
Bologna 5
Chiyoda-ku 5
Feasterville Trevose 5
Hyderabad 5
Moscow 5
Munich 5
Nuremberg 5
St Petersburg 5
Zurich 5
Augusta 4
Budapest 4
Englewood 4
Lima 4
Messina 4
Monmouth Junction 4
Naples 4
Stockholm 4
Tokyo 4
White Salmon 4
Adapazarı 3
Ankara 3
Barcelona 3
Bern 3
Cagliari 3
Cinisello Balsamo 3
Cosenza 3
Esslingen am Neckar 3
Genoa 3
Hot Springs 3
Jeddah 3
Kish 3
Kuala Lumpur 3
La Paz 3
Leawood 3
Madrid 3
Melbourne 3
Monza 3
Mumbai 3
Mussidan 3
Nanchang 3
Nijmegen 3
North Charleston 3
Padova 3
Ragusa 3
Sant Cugat del Vallès 3
Shanghai 3
Sharjah 3
Sydney 3
Taichung 3
Toronto 3
Warsaw 3
Wuhan 3
Zagreb 3
Çanakkale 3
Totale 2.559
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 134
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 98
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 75
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 74
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 67
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 55
Assessment of alopecia areata universalis successfully treated with upadacitinib 54
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 51
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 51
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 49
Biological agents targeting interleukin-13 for atopic dermatitis 49
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 47
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 47
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 44
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 44
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 43
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 42
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 42
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 41
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 40
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 40
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 39
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 38
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 38
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 37
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 36
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 36
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 36
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 36
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 35
Alexithymia affects patients with hidradenitis suppurativa 35
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 35
Dusky red swelling of the penis in association with fever and diarrhoea: a quiz. Metastatic Crohn's disease of the penis associated with enteric Crohn's disease 35
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 34
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 33
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 32
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 32
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 31
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 31
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 31
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 30
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 30
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 30
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 30
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 29
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 29
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 29
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 28
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 28
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study” 28
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 28
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 27
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 27
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 26
Topical treatment of severe xerosis: Results of an observational study 25
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting 25
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 25
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 24
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 24
Immunologic biomarkers for clinical and therapeutic management of psoriasis 24
Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: Joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) 24
Gynecomastia following isotretinoin treatment: A rare endocrine side effect 24
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern 24
European consensus statement on phenotypes of pustular psoriasis 24
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 23
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 23
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 23
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 23
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 22
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 21
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 21
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study 21
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 21
Optimizing acitretin use in patients with plaque psoriasis 21
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience 21
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 20
Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-α agents 20
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 19
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 19
Efficacy and safety of infliximab in psoriatic patients over the age of 65 19
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 19
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 19
Serum Protein Profile Changes in Psoriatic Patients Undergoing Treatment With Infliximab 18
UVA-1 Laser in the treatment of palmoplantar pustular psoriasis 18
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, atazanavir, emtricitabine, tenofovir) 18
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 17
The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry 17
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 17
Unmet needs in atopic dermatitis management: an expert consensus 17
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 16
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience 16
Secukinumab Drug Survival in Patients with Psoriasis: A multicenter, real-world, retrospective study 16
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 16
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 16
Elderly psoriatic patients under biological therapies: an Italian experience 16
Targeting IL-4 for the Treatment of Atopic Dermatitis 16
Immune response to vaccination in patients with psoriasis treated with systemic therapies 16
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience 16
A revolutionary therapeutic approach for psoriasis: Bispecific biological agents 16
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 16
Totale 3.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.282
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 2 0
2019/202098 13 1 1 1 0 3 1 15 1 18 32 12
2020/202194 2 2 3 6 3 6 5 23 11 12 20 1
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.490 45 374 116 272 85 252 121 90 39 93 3 0
Totale 4.081